Anaesthesia and new antithrombotic drugs

Current Opinion in Anaesthesiology

Volumn 18, Issue 3, 2005, Pages 353-359

  Vandermeulen, Erik ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Anaesthesia; Anticoagulant; Epidural; Spinal

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DESMOPRESSIN; DESULFATOHIRUDIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; IDRAPARINUX; LEPIRUDIN; LOTRAFIBAN; MELAGATRAN; ORBOFIBAN; PROTAMINE SULFATE; PROTHROMBIN COMPLEX; RAZAXABAN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SIBRAFIBAN; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; XEMILOFIBAN; XIMELAGATRAN;

ANAPHYLAXIS; ANESTHESIA; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; EPIDURAL ANESTHESIA; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; REVIEW; SPINAL ANESTHESIA; SPINAL CORD HEMORRHAGE; STROKE; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 20444363786     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aco.0000169246.96130.b7     Document Type: Review

References (59)

1. Gogarten W, Van Aken H, Büttner J, et al. Rückenmarksnahe Regionalanästhesien Und Thromboembolieprophylaxe/Antithrombotische Medikation. Anasthesiol Intensivmed 2003; 44:218-230.
2. Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the Second Asra Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003; 28:172-197.
3. Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks. Reg Anesth Pain Med 2004; 29(suppl):1-12. These are the most recent guidelines of the ASRA (the American Society of Regional Anesthesia and Pain Medicine) concerning the use of regional anaesthesia in anticoagulated patients.
4. Llau JV, de Andres J, Gomar C, et al. Drugs that alter hemostasis and regional anesthetic techniques: safety guidelines. Consensus conference [In Spanish]. Rev Esp Anestesiol Reanim 2001; 48:270-278.
5. Llau Pitarch JV, De Andres Ibanez J, Gomar Sancho C, et al. Hemostasis-altering drugs and regional anesthetic techniques: safety guidelines [In Spanish]. Rev Esp Anestesiol Reanim 2004; 51:137-142. This is the update of the Spanish guidelines concerning the use of regional anaesthesia in patients anticoagulated with the newest anticoagulants.
6. De Lange JJ, Van Kleef JW, Van Everdingen JJ. The Practice Guideline Neuraxis Blockade and Anticoagulation'. Ned Tijdschr Geneeskd 2004; 148:1528-1531. The guidelines of the national Dutch Society of Anaesthesiologists concerning the use of regional anaesthesia in anticoagulated patients.
7. Warkentin TE, Crowther MA. Reversing anticoagulants both old and new. Can J Anaesth 2002; 49:S11-S25.
8. Keam SJ, Goa KL. Fondaparinux Sodium. Drugs 2002; 62:1673-1685; discussion 1686-1687.
9. Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (Fondaparinux). Thromb Res 2003; 109:1-11.
10. Ansell J. New anticoagulants and their potential impact on the treatment of thromboembolic disease. Curr Hematol Rep 2004; 3:357-362. This paper reviews new developments in the field of factor Ua and Xa antagonists.
11. Davidson BL Preparing for the new anticoagulants. J Thromb Thrombolysis 2003; 16:49-54.
12. Paolucci F, Frasa H, Van Aarle F, et al. Two sensitive and rapid chromogenic assays of Fondaparinux Sodium (Arixtra) in human plasma and other biological matrices. Clin Lab 2003; 49:451-460.
13. Savi P, Chong BH, Greinacher A, et al. Effect of Fondaparinux on platelet activation in the presence of heparin-dependent antibodies. A blinded comparative multicenter study with unfractionated heparin. Blood 2005; 105:139-144. This is a well-designed study documenting the use of fondaparinux in patients with HIT.
14. Harenberg J, Jorg I, Fenyvesi T. Treatment of heparin-induced thrombocytopenia with Fondaparinux. Haematologica 2004; 89:1017-1018. Another interesting study with fondaparinux in patients with HIT.
15. Lagrange F, Vergnes C, Brun JL, et al. Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb Haemost 2002; 87:831-835.
16. Sanofi-Synthelabo, Organon N. Org31540/Sr90107a. Clinical Investigator Brochure; April 2001.
17. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs. Enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162:1833-1840.
18. Hardy JF. Best evidence in anesthetic practice: prevention: Fondaparinux is better than Enoxaparin for prevention of major venous thromboembolism after orthopedic surgery. Can J Anaesth 2003; 50:764-766.
19. Herbert JM, Herault JP, Bernat A, et al. Biochemical and pharmacological properties of Sanorg 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91:4197-4205.
20. Idraparinux Sodium: Sanorg 34006, SR 34006. Drugs R D 2004; 5:164-165.
21. Persist Investigators. A novel long-acting synthetic factor Xa inhibitor (Sanorg 34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J Thromb Haemost 2004; 2:47-53. This paper gives a good overview of the properties of a new long-acting factor Xa inhibitor that is not yet available.
22. Coller BS. Blockade of platelet GP IIb/IIIa receptors as an antithrombotic strategy. Circulation 1995; 92:2373-2380.
23. Alig L, Edenhofer A, Hadvary P, et al. Low molecular weight, non-peptide fibrinogen receptor antagonists. J Med Chem 1992; 35:4393-4407.
24. Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(suppl):234S-264S. These are the latest ACCP (the American College of Chest Physicians) guidelines on the use of all the antiplatelet agents currently available. It also contains a good review of their properties.
25. Steinhubl SR. Assessing platelet function during treatment with glycoprotein IIb/IIIa antagonists. Coronary Artery Dis 2003; 14:381-386.
26. Dasgupta H, Blankenship JC, Wood GC, et al. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J 2000; 140:206-211.
27. Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with Tirofiban or Eptifibatide is associated with antibodies specific for ligand-occupied GP IIb/IIIa. Blood 2002; 100:2071-2076.
28. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glyooprotein IIb/IIIa Antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001; 103:201-206.
29. Chew DP, Bhatt DL, Topol EJ. Oral glycoprotein IIb/IIIa inhibitors: Why don't they work? Am J Cardiovasc Drugs 2001; 1:421-428.
30. Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation 2001; 103:1479-1484.
31. Lubenow N, Greinacher A. Hirudin in heparin-induced thrombocytopenia. Semin Thromb Hemost 2002; 28:431-438.
32. Greinacher A. Lepirud: a bivalent direct thrombin inhibitor for anticoagulation therapy. Expert Rev Cardiovasc Ther 2004; 2:339-357. This paper is a comprehensive review of lepirudin, its effects, possible indications.
33. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003; 76:638-648.
34. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337: 1329-1335.
35. Greinacher A. Lepirudin for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. New York: Marcel Dekker; 2004. pp. 397-436. This is a chapter on lepirudin in the standard work on HIT by one of the leading experts. It gathers the most recent information on the subject.
36. Greinacher A, Eichler P, Albrecht D, et al. Antihirudin antibodies following low-dose subcutaneous treatment with: Desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood 2003; 101:2617-2619.
37. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with Lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003; 108:2062-2065.
38. Bartholomew JR. Bivalirudin for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. New York: Marcel Dekker; 2004. pp. 475-508. This is another chapter in the standard work on HIT that comments on the use of bivalirudin in patients with a history of HIT. It provides a complete overview of all that is currently worth knowing on the subject.
39. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein lib/ Ilia blockade during percutaneous coronary intervention: REPLACE-2 Randomized Trial. JAMA 2003; 289:853-863.
40. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs. heparin and planned glyco-protein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 Randomized Trial. JAMA 2004; 292:696-703. This paper demonstrates clearly that bivalirudin can really provide an asset during percutaneous coronary interventions.
41. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the bivalirudin angioplasty study. Am Heart J 2001; 142:952-959.
42. Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther 2002; 71:433-439.
43. Chew DP, Bhatt DL, Kimball W, et al. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol 2003; 92:919-923.
44. Eichler P, Lubenow N, Strobel U, Greinacher A. Antibodies against Lepirudin are polyspecific and recognize epitopes on bivalirudin. Blood 2004; 103:613-616. This study discusses the immunogenic cross-reactivity between the r-hirudins and the hirulogs.
45. Kaplan KL Direct thrombin inhibitors. Expert Opin Pharmacother 2003; 4:653-666.
46. Kathiresan S, Shiomura J, Jang IK. Argatroban. J Thromb Thrombolysis 2002; 13:41-47.
47. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of Argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20:318-329.
48. Fenyvesi T, Jorg I, Harenberg J. Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin Thromb Hemost 2002; 28:361-368.
49. Gustafsson D, Nystrom J, Carlsson S, et al. The direct thrombin inhibitor Melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101:171-181.
50. Eriksson UG, Bredberg U, Gislen K, et al. Pharmacokinetics and pharmacodynamics of Ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003; 59:35-43.
51. Eriksson UG, Bredberg U, Hoffmann KJ, et al. Absorption, distribution, metabolism, and excretion of Ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2003; 31:294-305.
52. Bredberg E, Andersson TB, Frison L, et al. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 2003; 42:765-777.
53. Elg M, Carlsson S, Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant factor Viia on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 2001; 101:145-157.
54. Rosencher N. Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery, efficacy, safety and anaesthetic considerations. Anaesthesia 2004; 59:803-810. This paper is probably the first anaesthesiological review of Ximelagatran in terms of thromboprophylactic efficacy and interactions with regional anaesthetic techniques.
55. Schulman S, Wahlander K, Lundstrom T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor Ximelagatran. N Engl J Med 2003; 349:1713-1721.
56. Eriksson H, Wahlander K, Gustafsson D, et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor Ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003; 1:41-47.
57. Halperin JL. Antithrombotic therapy in atrial fibrillation: Ximelagatran, an oral direct thrombin inhibitor. Expert Rev Cardiovasc Ther 2004; 2:163-174. This paper reviews the currently available results of phase III clinical trials investigating the use of Ximelagatran in atrial fibrillation.
58. Wallentin L, Wilcox RG, Weaver WD, et al. Oral Ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003; 362:789-797.
59. Boos CJ, More RS. Anticoagulation for non-valvular atrial fibrillation - towards a new beginning with Ximelagatran. Curr Control Trials Cardiovasc Med 2004; 5:3. This paper provides an evidence-based review of the efficacy of Ximelagatran in patients with atrial fibrillation when compared to warfarin and aspirin. It also describes liver-function abnormalities associated with the use of ximelagatran.